Agreed, however we do need capital. Hopefully we can do a tissue licensing deal in the interim to get us into initial human TAVR trials next year. It’s getting to the pointy end of things now. Irrespective of what happens the value on offer here is immense. IMO and DYOR.
Ann: DurAVR valve patient outcomes exceed expectations, page-9
-
- There are more pages in this discussion • 57 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$11.45 |
Change
-0.705(5.80%) |
Mkt cap ! $251.5M | |||
| Open | High | Low | Value | Volume |
| $12.15 | $12.15 | $11.27 | $161.4K | 13.84K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 235 | $11.32 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $11.56 | 74 | 3 |
View Market Depth
| Last trade - 11.47am 07/10/2024 (20 minute delay) ? |
| AVR (ASX) Chart |